Summary

Eligibility
for people ages 9-11 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCLA
Dates
study started
completion around

Description

Summary

Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well does the nonavalent HPV vaccine (which can prevent nine different types of HPV) work when given in an alternative dosing schedule to heathy young research participants.

Official Title

A Prospective, Single-arm, Open-label, Non-randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-booster Dosing Schedule Among 9-11 Year-old Girls and Boys

Details

Keywords

Human Papillomavirus-Related Carcinoma, Vaccines, Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Prevention (Gardasil 9)

Eligibility

Locations

  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles California 90095 United States
  • Banner University Medical Center - Tucson
    Tucson Arizona 85719 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT02568566
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 201 people participating
Last Updated